- Lexaria’s
patented DehydraTECH technology improves taste, achieves higher
absorption rates and promotes fast onset of bioactive compounds, including
nicotine and cannabinoids
- Nine
corporate licensees have signed a total of 11 definitive contracts to use
DehydraTECH technology in innovative beverages, edibles and oral products
- Lexaria
expects to experience unprecedented revenue growth as many of its clients
plan aggressive rollouts and growth for their product lines
Biotechnology company and drug delivery platform
innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)is expanding
its family of existing licensees and partners with an impressive lineup of new
corporate licensees for use of Lexaria’s patented DehydraTECH absorption
technology. A total of nine corporations have signed 11 definitive contracts to
use Lexaria’s revolutionary DehydraTECH drug delivery platform within their
existing and emerging brands, as the company detailed in a recent news release
(http://ibn.fm/tkN6e).
“The first half of 2019 delivered a period of unprecedented
achievements for Lexaria,” CEO Chris Bunka stated in a news release. “We signed
more license agreements than ever before in our Company’s history, many of
which were larger in scope than anything previous. We also launched our
brand-new business division Lexaria Nicotine which is disrupting nicotine
delivery methods that already attracted one of the world’s largest nicotine
companies, which has licensed our technology.”
Lexaria recently announced that it has discovered improved
performance characteristics in a new version of its DehydraTECH delivery
platform. An innovative use of a naturally sourced formulation enhancement more
than doubles DehydraTECH’s absorption performance, the company stated in a news
release (http://ibn.fm/9sZRc),
making the technology suitable for use in solid oral dosage forms like
capsules, tablets and pills for the pharmaceutical, medical and supplement
markets. New patent applications related to the recent innovations have been
filed.
Lexaria credits its recent commercial success mainly to its
ever-growing body of scientific results evidencing the superior capabilities
and power of its patented technologies. Recent technological advancements are
the result of one of the industry’s most focused and productive R&D
programs and hold promise for even higher levels of performance. In one 2019
animal study, combining Lexaria’s DehydraTECH with nanotech technologies
delivered increased quantities of CBD into brain tissue following oral ingestion
than certain existing industry formulations (http://ibn.fm/vWbd5).
Among the companies taking notice of Lexaria’s DehydraTECH
drug delivery platform by signing new license contracts are:
- Altria
Ventures Inc., an indirect wholly owned subsidiary of Altria Group Inc.,
for oral nicotine products; this license is signed with Lexaria Nicotine
LLC, a separate business division of Lexaria Bioscience Corp;
- Nuka
Enterprises LLC, for a new CBD/hemp license for beverages across the U.S.;
- Two
new worldwide beverages licenses to Hill Street Beverages (excluding
Mexico);
- Two
new joint manufacturing production licenses with Hill Street Beverages for
new, jointly owned cannabis and CBD brands;
- Three
new licenses with other companies for CBD beverages and edible CBD
ingredients/products across the U.S.;
- One
new license for cannabis beverages in California; and
- One
new multistate cannabis expansion license with Nuka Enterprises LLC for
its 1906 Brands for five states and two new product categories.
Lexaria expects to sign additional new definitive license
agreements through the balance of 2019 and beyond as demand for its
industry-leading technology continues to increase. Lexaria has multiple patents
pending in over 40 countries around the world and has patents granted in the
U.S. and Australia for utilization of its DehydraTECH delivery technology.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
